GlobeNewswire by notified

Statkraft and ABO Wind conclude 10-year power purchase agreement in Finland

Share
  • Statkraft receives electricity from Pajuperänkangas wind farm for ten years
  • Commissioning of the 14 turbines in Finland planned for 2023
  • ABO Wind covers the complete value chain of the 86.8-megawatt project

(Wiesbaden/Helsinki, 31 March 2022) Statkraft and ABO Wind have concluded a ten-year power purchase agreement (PPA) for the Finnish wind farm Pajuperänkangas. The Norwegian company also receives the rights to the Guarantees of Origins of the electricity produced.

The 14 turbines are scheduled to be connected to the grid in autumn 2023 and can produce enough electricity to supply approximately 14,000 electricity-heated Finnish households. With an installed capacity of 86.8 megawatts, it is the largest project to date in which ABO Wind covers the complete value-added chain of planning and turnkey construction. The development works have been previously carried out on a close partnership basis together with Infinergies Finland Oy.

"For us, the conclusion of the power purchase agreement is another milestone on the way to the independent implementation of a project of this size. We are very happy about the fact, that we are about to build our fourth wind farm in Haapajärvi this year and that we have found a reliable partner in Statkraft,” says Dr. Klaus Pötter, the ABO Wind General Manager responsible for Finland.

“Thanks to our solid capitalization ABO Wind is now in a position to generally develop wind farms such as Pajuperänkangas on its own and to construct them on a turnkey basis. Our internal financing and PPA departments also negotiated and concluded the power purchase agreement without external help," Pötter adds.

"Providing developers with the right power purchase agreement to enable the financing and construction of their projects while optimizing the risks over many years to come is one of Statkraft's core strengths. Our partnership with ABO Wind has been very positive and we are pleased to have contributed to quickly unlocking the next steps in the construction project thanks to our PPA," says Arne Wist, Head of Origination and Portfolio Management Nordics at Statkraft.

Currently, preparatory construction measures at the wind farm are underway. Construction of the foundations is scheduled to begin in the third quarter of this year. 14 V162 turbines with a hub height of 169 metres each will be erected. The wind farm helps increasing the renewable share in the Finnish energy mix, adding another significant share of emission-free electricity every year.

About ABO Wind:
ABO Wind successfully develops and builds wind and solar energy projects. Founded in 1996, the Germany-based company has realised more than 3,700 megawatts of capacity to date and built more than half of them. The company’s annual investment amounts to 500 million euros. More than 900 employees in 16 countries work with enthusiasm on the planning, financing, construction, operational management and maintenance of plants for a sustainable energy supply.

About Statkraft:
Statkraft is a leading company in hydropower internationally and Europe’s largest generator of renewable energy. The Group produces hydropower, wind power, solar power, gas-fired power and supplies district heating. Statkraft is a global company in energy market operations. Statkraft has 4,800 employees in 19 countries.

Contacts:

Dr. Daniel Duben, ABO Wind AG, +49 (0) 611 267 65-577, presse@abo-wind.de

Lars Magnus Günther, Statkraft AS, press spokesperson, +47 91 24 16 36, lars.gunther@statkraft.com

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

ObsEva to Present at the H.C. Wainwright Global Investment 2022 Conference16.5.2022 07:00:00 CEST | Press release

GENEVA, Switzerland May16, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, today announced that Company Management will provide a corporate update at the upcoming H.C. Wainwright Global Investment Conference, taking place virtually and in Miami, Florida from May 23 – 26, 2022. The presentation will be available on-demand through the H.C. Wainwright conference portal, starting at 10:30 a.m. EST on Tuesday, May 24, 2022. A webcast can be accessed here and will also be accessible under “Events Calendar” in the investors section of ObsEva’s website. About ObsEva ObsEva is a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on new therapies for the treatment of uterine fibroi

Zenas BioPharma Submits Investigational New Drug Application in China for ZB001 for the Treatment of Thyroid Eye Disease16.5.2022 00:00:00 CEST | Press release

WALTHAM, Mass. and SHANGHAI, China, May 15, 2022 (GLOBE NEWSWIRE) -- Zenas BioPharma, a global biopharmaceutical company committed to becoming a leader in the development and commercialization of immune-based therapies for patients in need around the world, today announced the submission of an investigational new drug (IND) application to the China National Medical Products Administration (NMPA) for the initiation of a Phase 1/2 clinical study of ZB001 for the treatment of Thyroid Eye Disease (TED). This study is designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ZB001. “The ZB001 IND submission to the NMPA marks a significant milestone for Zenas,” said Hua Mu, MD, PhD, Chief Executive Officer at Zenas. “There are currently no approved therapies for TED patients in China. Treatment options are limited and often involve high doses of steroids associated with serious side effects or surgical intervention. ZB001 has the potential to change the tre

Cool Company Ltd. – Mandatory Notification of Trade15.5.2022 14:52:24 CEST | Press release

EPS Ventures Ltd., close associate of Cyril Ducau, Chair of the Board of Cool Company Ltd. (the “Company”), has on 13 May 2022 acquired 38,419 shares in the Company at a price of NOK 84.63 per share. Following the transaction, EPS Ventures Ltd. holds a total of 15,038,419 shares in the Company, equivalent to 37.59% of the Company’s shares. Please see attached notification form in accordance with the Market Abuse Regulation article 19. This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. Attachment Primary insider notification form

Monthly information related to total number of voting rights and shares composing the share capital – April 30, 202213.5.2022 18:00:00 CEST | Press release

Monthly information related to total number of voting rights and shares composing the share capital –April 30, 2022. Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France Listing markets: Euronext Paris from Euronext (Market segment C - ISIN Code: FR0011471135- Symbol: ERYP) & Nasdaq Global Select Market in the United-States (Symbol : ERYP) Website : www.erytech.com DateTotal of shares composing the share capitalTotal of brut(1) voting rights Total of net (2) voting rights December 31, 202131 018 55332 518 33932 515 839January 31, 202231 018 55332 518 33932 515 839February 28, 202231 018 55332 518 54732 516 047March 31, 202231 018 55332 518 54732 516 047April 30, 202231 018 55332 518 54732 516 047 (1) Gross voting rights number (or « theoretical » voting rights) is used as a basis for calculating the crossing of the threshold. In accordance with article 223-11 of general regulation of Autorité des Marchés Financiers, this number is calculated on t

Hövding ansöker om avnotering från Nasdaq First North Growth Market13.5.2022 17:45:00 CEST | Pressemelding

Styrelsen för Hövding Sverige AB (publ) (”Hövding”) har beslutat att ansöka om avnotering av Hövdings aktie från Nasdaq First North Growth Market (”First North”). Sista dag för handel på First North kommer att meddelas efter att Hövding erhållit bekräftelse om detta från Nasdaq. Fosielund Holding AB (”Fosielund”) offentliggjorde genom pressmeddelande den 13 januari 2022 ett offentligt budpliktserbjudande till aktieägarna i Hövding (”Erbjudandet”). Fosielund meddelande genom pressmeddelande den 16 februari 2022 att Fosielund (med närstående), efter redovisning av likvid i Erbjudandet, innehade 18 021 741 aktier motsvarande ca 65 procent av aktierna och rösterna. Den 8 april 2022 meddelade Fosielund genom pressmeddelande att de förvärvat en större post aktier i Hövding, varefter Fosielund innehade ca 88,7 procent av aktierna och rösterna samt en avsikt att förvärva ytterligare aktier. Den 4 maj 2022 meddelade Fosielund genom pressmeddelande att de förvärvat ytterligare aktier och att des